3. Righini CA, De Fraipont F, Timsit JF, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res. 2007 Feb 15;13(4):1179-85. doi: 10.1158/1078-0432.CCR-06-2027. PMID: 17317827.
4. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science. 2000 Mar 17;287(5460):2017-9. doi: 10.1126/science.287.5460.2017. PMID: 10720328.
6. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A, Seilanian-Toosi M. Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract. 2009 Nov 1;10(6): E001-8. PMID: 20020075.
7. Bigler LR, Streckfus CF, Dubinsky WP. Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med. 2009, 29(1):71-85. doi: 10.1016/j.cll.2009.01.004. PMID: 19389552.
8. Bolyarova T, Petkova S. Determination of concentration levels of some markers of inflamation and destruction in saliva and gingival exudate for diagnosing periodontal diseases. Gen medicine, 2016; 18(4): 56-65.
9. Bolyarova-Konova TN, Stefanov LD, Kolarov ZG, et al. ACPA in Saliva and their Association with Periodontitis and Rheumatoid Arthritis. Rheumatology. 2020; 28(1):20-30.
10. Khurshid Z, Zohaib S, Najeeb S, et al. Human Saliva Collection Devices for Proteomics: An Update. Int J Mol Sci. 2016 Jun 6;17(6):846. doi: 10.3390/ijms17060846. PMID: 27275816; PMCID: PMC4926380.
12. Messana I, Cabras T, Iavarone F, et al. Chrono-proteomics of human saliva: variations of the salivary proteome during human development. J Proteome Res. 2015 Apr 3;14(4):1666-77. doi: 10.1021/pr501270x. Epub 2015 Mar 19. PMID: 25761918.
13. Morgan E, Varro R, Sepulveda H, et al. Cytometric bead array: A multiplexed assay platform with applications in various areas of biology. Clin Immunol. 2004, 110, 252-266.
15. Brailo V, Vacicevic-Boras V, Cekic-Arambasin A, et al. The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia. Oral Oncol 2006;42:370-3.
16. Katakura A, Kamiyama I, Takano N, et al. Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll. 2007 Nov;48(4):199-203. doi: 10.2209/tdcpublication.48.199. PMID: 18360107.
17. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008 Aug 15;113(4):750-7. doi: 10.1002/cncr.23615. PMID: 18536030.
18. Sahibzada HA, Khurshid Z, Khan RS, et al. Salivary IL-8, IL-6 and TNF-Į as potential diagnostic biomarkers for oral cancer. Diagnostics. 2017, 7, 21.
20. Saheb Jamee M, Eslami M, Atarbashi Moghadam F, Sarafnejad A. Salivary concentration of TNF, IL1, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2008, 13, E292–E295.
21. Fallon PG, Jolin HE, Smith P et al. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 2002, 17, 7-17.
22. Shree KH, Ramani P, Sherlin H, et al. Saliva as a Diagnostic Tool in Oral Squamous Cell Carcinoma ² A Systematic Review with Meta-Analysis. Pathol. Oncol. Res. 2019.
23. St John MA, Li Y, Zhou X, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):929-35. doi: 10.1001/archotol.130.8.929. PMID: 15313862.
24. Krishnan R, Thayalan DK, Padmanaban R et al. Association of serum and salivary tumor necrosis factor-Į with histological grading in oral cancer and its role in differentiating premalignant and malignant oral disease. Asian Pac J Cancer Prev. 2013; 15(17): 7141-7148.
25. Rhodus NL, Ho V, Miller CS, et al. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev. 2005;29(1):42-5. doi: 10.1016/j.cdp.2004.10.003. Epub 2005 Jan 28. PMID: 15734216.
27. Katakura A, Kamiyama I, Takano N, et al. Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll. 2007 Nov;48(4):199-203. doi: 10.2209/tdcpublication.48.199. PMID: 18360107.
29. Rescala B, Rosalem W-Jr, Teles RP et al. Immunologic and Microbiologic Profiles of Chronic and Aggressive Periodontitis Subjects. J Periodontol. 2010, 8, 1308-1316.
31. Gursoy UK, Könönen E, Uitto VJ, et al. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36(11):922-7. doi: 10.1111/j.1600-051X.2009.01480.x. Epub 2009 Oct 2. PMID: 19799718.
32. Taylor JJ. Protein biomarkers of periodontitis in saliva. ISRN Inflamm. 2014 Apr 22;2014:593151. doi: 10.1155/2014/593151. PMID: 24944840; PMCID: PMC4040190.
33. Preshaw PM, Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? J Clin Periodontol. 2011 Mar;38 Suppl 11:60-84. doi: 10.1111/j.1600-051X.2010.01671.x. PMID: 21323705.
34. Arellano-Garcia ME, Hu S, Wang J, et al. Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 2008 Nov;14(8):705-12. doi: 10.1111/j.1601-0825.2008.01488.x. PMID: 19193200; PM-CID: PMC2675698.
35. Roi A, Roi CI, Negruţiu ML, et al. The Challenges of OSCC Diagnosis: Salivary Cytokines as Potential Biomarkers. J Clin Med. 2020 Sep 4;9(9): E2866. doi: 10.3390/jcm9092866. PMID: 32899735.
36. Kinane DF, Preshaw PM, Loos BG, Working Group 2 of Seventh European Workshop on Periodontology. Host-response: understanding the cellular and molecular mechanisms of host-microbial interactions--consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol. 2011 Mar;38 Suppl 11:44-8. doi: 10.1111/j.1600-051X.2010.01682.x. PMID: 21323703.
37. Takeuchi E, Yanagawa H, Suzuki Y, et al. Comparative analysis of interleukin-15 and interleukin-2 for induction of killer activity and of type 2 cytokine production by mononuclear cells from lung cancer patients. Br J Cancer. 1998, 78: 616-620.
38. Aziz S, Ahmed SS, Ali A et al. Salivary immunosuppressive cytokines IL-10 and IL-13 are significantly elevated in oral squamous cell carcinoma patients. Cancer Invest. 2015; 33(7): 318-328.
39. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4 and CD8 regulatory T cells. J Immunol. 2006 Jul 15;177(2):896-904. doi: 10.4049/jimmunol.177.2.896. PMID: 16818744.38
44. Geng XF, Du M, Han JX, et al. Saliva CA125 and TPS levels in patients with oral squamous cell carcinoma. Int J Biol Markers. 2013 Apr-Jun;28(2):216-20. doi: 10.5301/jbm.5000001. Epub 2013 Apr 15. PMID: 23613350.43.
45. Balan JJ, Rao RS, Premalatha BR, Patil S. Analysis of tumor marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: a comparative study. J Contemp Dent Pract. 2012 Sep 1;13(5):671-5. doi: 10.5005/jp-journals-10024-1207. PMID: 23250173.44.
46. Alyasiri NS, Mehdi SJ, Alam MS et al. PTEN-mediated AKT activation contributes to the reduced apoptosis among Indian oral squamous cell carcinoma patients. J Cancer Res Clin Oncol, 2012, 138(1), 103-109. https://doi.org/10.1007/s00432-011-1077-y;60.45.
47. Liu C, Chan CB, Ye K. 7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders. Translational Neurodegeneration, 2016, 5, 2. https://doi.org/10.1186/s40035-015-0048-7.46.
48. Zou W, Hu X, Jiang L. Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling. Curr Cancer Drug Targets. 2020;20(10):779-788. doi: 10.2174/156800 9620999200730183631. PMID: 32748747.47.
50. Lin TA, Wu TS, Li YJ, et al. Role and Mechanism of LIF in Oral Squamous Cell Carcinoma Progression. J Clin Med. 2020 Jan 21;9(2):295. doi: 10.3390/jcm9020295. PMID: 31973037; PMCID: PMC7073607.49.